Jeku

Jeku is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of hematologic malignancies and solid tumors. The company specializes in chimeric antigen receptor T-cell (CAR-T) technologies, leveraging its proprietary platform to engineer highly specific and potent immune cells. Jeku's pipeline includes several next-generation CAR-T candidates targeting well-validated antigens such as CD19 and BCMA, as well as novel targets for difficult-to-treat cancers. By optimizing cell manufacturing processes and enhancing the persistence of engineered cells, Jeku aims to provide more effective and accessible treatment options for patients with advanced cancers.